Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
News > Health News
Audio By Carbonatix
1:15 PM on Monday, June 1
The Associated Press
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.
To access the live webcast, please use the following information:
Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub
Date: Wednesday, June 17, 2026
Time: 10:30 a.m. Pacific time
Webcast: https://event.summitcast.com/view/bpjo3VVjZ25pp6SXpUua92/j8zQrjvPykncFs66WaA7AS
Management also will be conducting investor meetings at the conference on June 17-18. If you would like to schedule a 1x1 investor meeting with Aytu, and to attend the Planet MicroCap Las Vegas 2026 investor conference, please make sure you are registered here: REGISTER. Meetings will be scheduled and conducted in person at the conference venue: Bellagio Resort & Hotel in Las Vegas, NV. The Planet MicroCap Las Vegas 2026 investor conference website is available here: HOME PAGE.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
Robert Blum
Lytham Partners
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
